Form 8-K - Current report:
SEC Accession No. 0001628280-25-004197
Filing Date
2025-02-06
Accepted
2025-02-06 08:13:57
Documents
22
Period of Report
2025-02-06
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K sgmo-20250206.htm   iXBRL 8-K 61184
5 GRAPHIC sgmo-20250206_g1.jpg GRAPHIC 163916
6 GRAPHIC sgmo-20250206_g2.jpg GRAPHIC 395124
7 GRAPHIC sgmo-20250206_g3.jpg GRAPHIC 130840
8 GRAPHIC sgmo-20250206_g4.jpg GRAPHIC 74478
9 GRAPHIC sgmo-20250206_g5.jpg GRAPHIC 68945
10 GRAPHIC sgmo-20250206_g6.jpg GRAPHIC 71686
11 GRAPHIC sgmo-20250206_g7.jpg GRAPHIC 60921
12 GRAPHIC sgmo-20250206_g8.jpg GRAPHIC 178181
13 GRAPHIC sgmo-20250206_g9.jpg GRAPHIC 118668
  Complete submission text file 0001628280-25-004197.txt   3047737

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20250206.xsd EX-101.SCH 1824
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20250206_lab.xml EX-101.LAB 21880
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20250206_pre.xml EX-101.PRE 12547
24 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20250206_htm.xml XML 2714
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 25595536
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)